Drug
Brexpiprazole
Brexpiprazole: highest development phase Phase 3, developed by Lundbeck, Otsuka. 15 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck, Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brexpiprazole (OPC-34712) NCT03198078 | Phase 3 | Schizophrenia |
| Brexpiprazole NCT03594123 | Phase 3 | Alzheimer's Disease |
| Brexpiprazole NCT02054702 | Phase 3 | Schizophrenia |
| Brexpiprazole NCT03259555 | Phase 3 | Bipolar I Disorder |
| Brexpiprazole NCT01942785 | Phase 3 | Major Depressive Disorder |
| Brexpiprazole NCT04174365 | Phase 3 | Irritability Associated With Autism Spectrum Disorder (ASD) |
| Brexpiprazole NCT02013531 | Phase 3 | Major Depressive Disorder |
| brexpiprazole NCT02758067 | Phase 3 | Schizophrenia |
| Brexpiprazole NCT01668797 | Phase 3 | Acute Schizophrenia |
| Brexpiprazole NCT01838681 | Phase 3 | Major Depressive Disorder |
| Brexpiprazole NCT01987960 | Phase 3 | Post-traumatic Stress Disorder |
| Brexpiprazole NCT02212613 | Phase 3 | Major Depressive Disorder and Irritability |
| Brexpiprazole NCT01670279 | Phase 1 | Major Depressive Disorder |
| Brexpiprazole (OPC-34712) NCT02411695 | Phase 1 | Schizophrenia |
| Brexpiprazole NCT03734302 | Phase 1 | Healthy |
Latest
No recent events.
Follow Brexpiprazole on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.